Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Children's National Health System, Washington D.C., District of Columbia M.D. Anderson Cancer Center (MDACC), Houston, Texas